Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to 32.39%.

  • Biodesix's EBITDA Margin rose 149400.0% to 32.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.61%, marking a year-over-year increase of 123500.0%. This contributed to the annual value of 48.37% for FY2024, which is 358500.0% up from last year.
  • Latest data reveals that Biodesix reported EBITDA Margin of 32.39% as of Q3 2025, which was up 149400.0% from 48.55% recorded in Q2 2025.
  • Biodesix's 5-year EBITDA Margin high stood at 19.34% for Q1 2021, and its period low was 220.85% during Q1 2022.
  • Its 5-year average for EBITDA Margin is 91.71%, with a median of 74.38% in 2024.
  • As far as peak fluctuations go, Biodesix's EBITDA Margin surged by 1459300bps in 2021, and later tumbled by -2015000bps in 2022.
  • Over the past 5 years, Biodesix's EBITDA Margin (Quarter) stood at 161.67% in 2021, then rose by 11bps to 144.58% in 2022, then soared by 68bps to 46.84% in 2023, then soared by 31bps to 32.55% in 2024, then rose by 0bps to 32.39% in 2025.
  • Its last three reported values are 32.39% in Q3 2025, 48.55% for Q2 2025, and 50.87% during Q1 2025.